SEC Form 4 · accession 0001106578-26-000081
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairperson & CEO · Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 18, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 17, 2026 | M | 9,500 | $146.03 | A | 50,013 | D | |
| Common StockF2 | Jun 17, 2026 | S | 560 | $548.5743 | D | 49,453 | D | |
| Common StockF3 | Jun 17, 2026 | S | 612 | $549.5723 | D | 48,841 | D | |
| Common StockF4 | Jun 17, 2026 | S | 2,077 | $550.8694 | D | 46,764 | D | |
| Common StockF5 | Jun 17, 2026 | S | 1,840 | $551.727 | D | 44,924 | D | |
| Common StockF6 | Jun 17, 2026 | S | 727 | $552.7527 | D | 44,197 | D | |
| Common StockF7 | Jun 17, 2026 | S | 1,201 | $553.7782 | D | 42,996 | D | |
| Common StockF8 | Jun 17, 2026 | S | 1,909 | $554.7714 | D | 41,087 | D | |
| Common StockF9 | Jun 17, 2026 | S | 574 | $555.6286 | D | 40,513 | D | |
| Common Stock | holding | — | — | — | 166 | I | by Spouse | |
| Common StockF10 | holding | — | — | — | 324,443 | I | by Trust | |
| Common StockF11 | holding | — | — | — | 249,108 | I | by Trust | |
| Common StockF12 | holding | — | — | — | 45,596 | I | by Trust | |
| Common StockF13 | holding | — | — | — | 8,902 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option | $146.03 | Jun 17, 2026 | M | 9,500 | D | Mar 15, 2020 | Mar 15, 2027 | Common Stock | 9,500 | 12,410 | D |
Explanation of responses
- F1This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F11Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F12Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F13Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F2This transaction was executed in multiple trades at prices ranging from $548.13 to $549.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $549.14 to $550.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $550.19 to $551.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $551.23 to $552.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $552.285 to $553.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $553.30 to $554.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8This transaction was executed in multiple trades at prices ranging from $554.30 to $555.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9This transaction was executed in multiple trades at prices ranging from $555.55 to $555.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.